Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinisches Magazin 6/2015

01.12.2015 | Onkologie

Renaissance eines alten Bekannten

Bedeutung des Androgenrezeptors beim Mammakarzinom

verfasst von: Dr. Gabriel Rinnerthaler

Erschienen in: Wiener klinisches Magazin | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

In diesem Übersichtsartikel wird der prognostische und therapeutische Stellenwert einer Androgenrezeptorexpression beim Mammakarzinom näher beleuchtet. Durch das zunehmend bessere Verständnis der Tumorbiologie, wie auch durch die Entwicklung neuer gegen den Androgenrezeptor gerichteter Therapien, gewinnt der Androgenrezeptor in der Behandlung des Mammakarzinoms zunehmend an Bedeutung. Vor allem Enzalutamid, ein Antiandrogen der zweiten Generation, ist eine sehr vielversprechende zielgerichtete Therapie bei androgenrezeptorpositiven triple-negativen Mammakarzinomen.
Literatur
1.
Zurück zum Zitat Ogawa Y, Hai E, Matsumoto K et al (2008) Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol / Japan Society of Clinical Oncology 13:431–435 Ogawa Y, Hai E, Matsumoto K et al (2008) Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol / Japan Society of Clinical Oncology 13:431–435
2.
Zurück zum Zitat Burger HG (2002) Androgen production in women. Fertil Steril 77(Suppl 4):S3–5 Burger HG (2002) Androgen production in women. Fertil Steril 77(Suppl 4):S3–5
3.
Zurück zum Zitat Bajetta E, Martinetti A, Zilembo N et al (2002) Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism. Ann Oncol 13:1059–1066 Bajetta E, Martinetti A, Zilembo N et al (2002) Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism. Ann Oncol 13:1059–1066
4.
Zurück zum Zitat Forward DP, Cheung KL, Jackson L et al (2004) Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. British journal of cancer 90:590–594 Forward DP, Cheung KL, Jackson L et al (2004) Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. British journal of cancer 90:590–594
5.
Zurück zum Zitat Vera-Badillo FE, Templeton AJ, De Gouveia P et al (2014) Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst 106:djt319 Vera-Badillo FE, Templeton AJ, De Gouveia P et al (2014) Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst 106:djt319
6.
Zurück zum Zitat Qu Q, Mao Y, Fei XC et al (2013) The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS One 8:e82650 Qu Q, Mao Y, Fei XC et al (2013) The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS One 8:e82650
7.
Zurück zum Zitat Collins LC, Cole KS, Marotti JD et al. (2011) Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod Pathol 24:924–931 Collins LC, Cole KS, Marotti JD et al. (2011) Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod Pathol 24:924–931
8.
Zurück zum Zitat Mcnamara KM, Moore NL, Hickey TE et al (2014) Complexities of androgen receptor signalling in breast cancer. Endocr-Rel Cancer 21:T161–181 Mcnamara KM, Moore NL, Hickey TE et al (2014) Complexities of androgen receptor signalling in breast cancer. Endocr-Rel Cancer 21:T161–181
9.
Zurück zum Zitat Hanamura T, Niwa T, Nishikawa S et al (2013) Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism. Breast Cancer Res Treat 139:731–740 Hanamura T, Niwa T, Nishikawa S et al (2013) Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism. Breast Cancer Res Treat 139:731–740
10.
Zurück zum Zitat Ando S, De Amicis F, Rago V et al (2002) Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol 193:121–128 Ando S, De Amicis F, Rago V et al (2002) Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol 193:121–128
11.
Zurück zum Zitat Mayer IA, Abramson VG, Lehmann BD et al (2014) New strategies for triple-negative breast cancer – deciphering the heterogeneity. Clin Cancer Res 20:782–790 Mayer IA, Abramson VG, Lehmann BD et al (2014) New strategies for triple-negative breast cancer – deciphering the heterogeneity. Clin Cancer Res 20:782–790
12.
Zurück zum Zitat Mcnamara KM, Yoda T, Nurani AM et al (2014) Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes. Breast Cancer Res Treat 145:281–293 Mcnamara KM, Yoda T, Nurani AM et al (2014) Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes. Breast Cancer Res Treat 145:281–293
13.
Zurück zum Zitat Garay JP, Park BH (2012) Androgen receptor as a targeted therapy for breast cancer. Am J Cancer Res 2:434–445 Garay JP, Park BH (2012) Androgen receptor as a targeted therapy for breast cancer. Am J Cancer Res 2:434–445
14.
Zurück zum Zitat Gucalp A, Tolaney S, Isakoff SJ et al (2013) Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res 19:5505–5512 Gucalp A, Tolaney S, Isakoff SJ et al (2013) Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res 19:5505–5512
15.
Zurück zum Zitat O’Shaughnessy J et al (2014) Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor. ASCO annual meeting 2014 #519 O’Shaughnessy J et al (2014) Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor. ASCO annual meeting 2014 #519
16.
Zurück zum Zitat Traina TA et al (2015) Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). ASCO annual meeting 2015 #1003 Traina TA et al (2015) Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). ASCO annual meeting 2015 #1003
17.
Zurück zum Zitat Parker JS (2015) A novel biomarker to predict sensitivity to enzalutamide (ENZA) in TNBC. ASCO annual meeting 2015 #1083 Parker JS (2015) A novel biomarker to predict sensitivity to enzalutamide (ENZA) in TNBC. ASCO annual meeting 2015 #1083
18.
Zurück zum Zitat Overmoyer B et al (2014) Enobosarm for the treatment of metastatic, estrogen and androgen receptor positive, breast cancer. Final results of the primary endpoint and current progression free survival. San Antonio Breast Cancer Symposium 2014 #P1-13-04 Overmoyer B et al (2014) Enobosarm for the treatment of metastatic, estrogen and androgen receptor positive, breast cancer. Final results of the primary endpoint and current progression free survival. San Antonio Breast Cancer Symposium 2014 #P1-13-04
Metadaten
Titel
Renaissance eines alten Bekannten
Bedeutung des Androgenrezeptors beim Mammakarzinom
verfasst von
Dr. Gabriel Rinnerthaler
Publikationsdatum
01.12.2015
Verlag
Springer Vienna
Erschienen in
Wiener klinisches Magazin / Ausgabe 6/2015
Print ISSN: 1869-1757
Elektronische ISSN: 1613-7817
DOI
https://doi.org/10.1007/s00740-015-0076-z